Prostate Cancer

EP. 1: Case 1: 64-Year-Old African American Man With nmCRPC

November 19th 2019

EP. 2: Case 1: The Importance of PSA Doubling Time in Prostate Cancer

November 19th 2019

EP. 3: Case 1: Initiating Patients on AR-Targeted Therapy in nmCRPC

November 19th 2019

EP. 4: Case 1: Differences in AR-Targeted Therapy Adverse Events in nmCRPC

November 19th 2019

EP. 5: Case 1: Patient Choice in Initiating AR-Targeted Therapy in nmCRPC

November 19th 2019

EP. 6: Case 2: 64-Year-Old White Male With mCSPC

November 19th 2019

EP. 7: Case 2: High-Volume Versus Low-Volume Metastatic CSPC

November 19th 2019

EP. 8: Case 2: Combination Therapy Options in Metastatic CSPC

November 19th 2019

EP. 9: Case 2: Challenges Treating CSPC With Visceral Metastases

November 19th 2019

EP. 10: Case 2: Sequencing Therapy in mCSPC

November 19th 2019

EP. 11: Case 2: Local Control in Metastatic CSPC

November 19th 2019

EP. 12: Case 3: 72-Year-Old Man With mCRPC

November 19th 2019

EP. 13: Case 3: Factors to Consider in mCRPC Treatment

November 19th 2019

EP. 14: Case 3: Treatment After Progression to mCRPC

November 19th 2019

EP. 15: Case 3: Personalizing Treatment for mCRPC

November 19th 2019

EP. 16: Case 3: Clinical Relevance of the AR-V7 Biomarker in mCRPC

November 19th 2019

EP. 17: Case 3: Use of Radium-223 in mCRPC

November 19th 2019

EP. 18: Additional Insights: The Presentation of Prostate Cancer

November 19th 2019

EP. 19: Additional Insights: Novel Agents in Prostate Cancer

November 19th 2019

EP. 20: Additional Insights: Androgen Receptor Inhibitor Adverse Events

November 19th 2019

EP. 21: Additional Insights: Management of Toxicities in AR Therapy

November 19th 2019

EP. 22: Additional Insights: Keeping Up With Advances in Prostate Cancer

November 19th 2019

EP. 23: Agarwal Discusses the Updated Results of the TITAN Trial of Apalutamide in mHSPC

June 29th 2021

Neeraj Agarwal, MD, discusses the updated results of the phase 3 TITAN study, which analyzed the efficacy of apalutamide plus androgen deprivation therapy versus ADT plus placebo in patients with metastatic hormone-sensitive prostate cancer.

Prostate Cancer

EP. 1: Case 1: 64-Year-Old African American Man With nmCRPC

EP. 2: Case 1: The Importance of PSA Doubling Time in Prostate Cancer

EP. 3: Case 1: Initiating Patients on AR-Targeted Therapy in nmCRPC

EP. 4: Case 1: Differences in AR-Targeted Therapy Adverse Events in nmCRPC

EP. 5: Case 1: Patient Choice in Initiating AR-Targeted Therapy in nmCRPC

EP. 6: Case 2: 64-Year-Old White Male With mCSPC

EP. 7: Case 2: High-Volume Versus Low-Volume Metastatic CSPC

EP. 8: Case 2: Combination Therapy Options in Metastatic CSPC

EP. 9: Case 2: Challenges Treating CSPC With Visceral Metastases

EP. 10: Case 2: Sequencing Therapy in mCSPC

EP. 11: Case 2: Local Control in Metastatic CSPC

EP. 12: Case 3: 72-Year-Old Man With mCRPC

EP. 13: Case 3: Factors to Consider in mCRPC Treatment

EP. 14: Case 3: Treatment After Progression to mCRPC

EP. 15: Case 3: Personalizing Treatment for mCRPC

EP. 16: Case 3: Clinical Relevance of the AR-V7 Biomarker in mCRPC

EP. 17: Case 3: Use of Radium-223 in mCRPC

EP. 18: Additional Insights: The Presentation of Prostate Cancer

EP. 19: Additional Insights: Novel Agents in Prostate Cancer

EP. 20: Additional Insights: Androgen Receptor Inhibitor Adverse Events

EP. 21: Additional Insights: Management of Toxicities in AR Therapy

EP. 22: Additional Insights: Keeping Up With Advances in Prostate Cancer

EP. 23: Agarwal Discusses the Updated Results of the TITAN Trial of Apalutamide in mHSPC

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

CLL Treatment Enters a New Era of Targeted Combinations

Expanding the Role of Immunotherapy in Lymphoma

SurVaxM Improves OS Only in Younger Subgroup in Newly Diagnosed Glioblastoma

Psilocybin-Assisted Therapy Aims at Existential Distress in Lung Cancer

AI in Precision Oncology: A Paradigm Shift